Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$0.46 USD
+0.02 (3.86%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $0.46 0.00 (0.66%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Unicycive Therapeutics, Inc. [UNCY]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
OLC Is a Triple Threat on Tolerability/Safety, With Upside on Efficacy and Pill Burden; NDA Filing in 3Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
New Analyses of OLC and UNI-494 Presented at ERA Congress
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap: OLC Pivotal Top-line Data Readout on Target in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
4Q Recap; OLC Pivotal Trial Topline Readout on Target in Late 2Q24; We Anticipate FDA Approval in Mid-2025; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Preclinical Study Shows UNI-494''s Potential For DGF in Kidney Transplant Patients; Full Phase 1 Data in 2H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
OLC Pivotal Trial Completed Enrollment; Topline Data Expected in Late 2Q24 to Support NDA Submission; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
UNI-494 Granted Orphan Drug Designation For Delayed Graft Function in Kidney Transplant Patients; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Letter to Shareholders Confirms OLC Pivotal Trial Top-Line Readout on Target in 2Q24 as Next Major Milestone; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
First Patient Enrolled in Pivotal Trial of OLC In Line With 4Q23 Target; Topline Data in 2Q24 Complete NDA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap; With FDA Alignment on OLC''s Regulatory Path
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
2Q Recap; We Await FDA Alignment on New OLC Study Design to Support NDA; PT to $4.50 on Equity Dilution; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Lanthanum Dioxycarbonate Now Known As Oxylanthanum Carbonate; We Await Details of New Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
We Assume New FDA Request Delays NDA Filing for LDC by Six Months; Reduce PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Need for Clinical Data in CKD Patients on Dialysis Delays NDA Filing
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
ERA 2023 Data Highlight UNI-494''s Mechanism in Animal Models; Renazorb 3Q23 NDA Filing As Next Milestone; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Unicycive Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap; NDA Submission Planned for 3Q23; Commercial Preparations Are Underway For 2024 U.S. Launch; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E